Envista Holdings Corporation (NYSE:NVST - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the sixteen brokerages that are currently covering the stock, MarketBeat reports. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $29.3077.
NVST has been the subject of a number of research reports. Wall Street Zen raised shares of Envista from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Weiss Ratings upgraded Envista from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, August 6th. BMO Capital Markets began coverage on Envista in a research note on Wednesday, July 8th. They set a "market perform" rating and a $27.00 price objective for the company. Zacks Research upgraded Envista from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. Finally, Morgan Stanley set a $23.00 target price on Envista in a report on Thursday, August 6th.
Read Our Latest Stock Report on NVST
Envista Price Performance
Envista stock opened at $27.21 on Friday. The stock has a market capitalization of $4.37 billion, a P/E ratio of 46.91, a P/E/G ratio of 1.28 and a beta of 0.86. The company's fifty day moving average price is $26.90 and its 200 day moving average price is $26.28. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. Envista has a 1 year low of $18.77 and a 1 year high of $30.42.
Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.07. The company had revenue of $730.50 million during the quarter, compared to analysts' expectations of $716.11 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm's revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts anticipate that Envista will post 1.53 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in Envista by 1,442.7% during the 4th quarter. Millennium Management LLC now owns 2,420,615 shares of the company's stock worth $52,552,000 after purchasing an additional 2,263,712 shares during the last quarter. Holocene Advisors LP acquired a new stake in shares of Envista in the second quarter valued at about $43,936,000. Arrowstreet Capital Limited Partnership raised its position in shares of Envista by 341.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company's stock valued at $72,515,000 after buying an additional 2,210,847 shares during the last quarter. Norges Bank purchased a new position in shares of Envista in the fourth quarter worth about $45,113,000. Finally, Wellington Management Group LLP lifted its stake in shares of Envista by 2,662.1% in the second quarter. Wellington Management Group LLP now owns 1,686,415 shares of the company's stock worth $44,437,000 after buying an additional 1,625,360 shares in the last quarter.
About Envista
(
Get Free Report)
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company's offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista's product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.